GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (OTCPK:GHSI) » Definitions » ROE %

GHSI (Guardion Health Sciences) ROE % : 481.19% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Guardion Health Sciences's annualized net income for the quarter that ended in Jun. 2024 was $41.30 Mil. Guardion Health Sciences's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was $8.58 Mil. Therefore, Guardion Health Sciences's annualized ROE % for the quarter that ended in Jun. 2024 was 481.19%.

The historical rank and industry rank for Guardion Health Sciences's ROE % or its related term are showing as below:

GHSI' s ROE % Range Over the Past 10 Years
Min: -162.63   Med: -142.96   Max: 79.19
Current: 79.19

During the past 9 years, Guardion Health Sciences's highest ROE % was 79.19%. The lowest was -162.63%. And the median was -142.96%.

GHSI's ROE % is ranked better than
98.13% of 965 companies
in the Drug Manufacturers industry
Industry Median: 4.49 vs GHSI: 79.19

Guardion Health Sciences ROE % Historical Data

The historical data trend for Guardion Health Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences ROE % Chart

Guardion Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only -142.96 -83.44 -160.61 -84.15 1.48

Guardion Health Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.63 19.97 21.45 -328.51 481.19

Competitive Comparison of Guardion Health Sciences's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's ROE % falls into.



Guardion Health Sciences ROE % Calculation

Guardion Health Sciences's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=0.158/( (13.168+8.146)/ 2 )
=0.158/10.657
=1.48 %

Guardion Health Sciences's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Mar. 2024 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=41.296/( (3.414+13.75)/ 2 )
=41.296/8.582
=481.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Guardion Health Sciences  (OTCPK:GHSI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=41.296/8.582
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(41.296 / 0.292)*(0.292 / 12.853)*(12.853 / 8.582)
=Net Margin %*Asset Turnover*Equity Multiplier
=14142.47 %*0.0227*1.4977
=ROA %*Equity Multiplier
=321.03 %*1.4977
=481.19 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=41.296/8.582
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (41.296 / -8.532) * (-8.532 / -5.468) * (-5.468 / 0.292) * (0.292 / 12.853) * (12.853 / 8.582)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -4.8401 * 1.5604 * -1872.6 % * 0.0227 * 1.4977
=481.19 %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Guardion Health Sciences ROE % Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences Business Description

Traded in Other Exchanges
N/A
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc clinical nutrition company that develops and distributes clinically supported dietary supplements and medical foods. It offers a portfolio of science-based, clinically supported products designed to support consumers, healthcare professionals and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.
Executives
Bradley Louis Radoff 10 percent owner 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Katharine Joan Cox officer: Chief Accounting Officer 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall officer: CEO & President 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Family Foundation Radoff other: See Footnote 1 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs director 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes director, officer: Chief Executive Officer 2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano director 131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin officer: Chief Accounting Officer 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan officer: Chief Commercial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans director, officer: Chief Scientific Officer 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans 10 percent owner 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
John Townsend other: Controller 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Gordon Bethwaite officer: Vice Pres, Sales and Marketing 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128

Guardion Health Sciences Headlines

From GuruFocus